
PRTG Valuation
Portage Biotech Inc
- Overview
- Forecast
- Valuation
- Earnings
PRTG Relative Valuation
PRTG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRTG is overvalued; if below, it's undervalued.
Historical Valuation
Portage Biotech Inc (PRTG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.07. The fair price of Portage Biotech Inc (PRTG) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:5.70
Fair
-0.57
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Portage Biotech Inc. (PRTG) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.58
EV/EBIT
Portage Biotech Inc. (PRTG) has a current EV/EBIT of -0.58. The 5-year average EV/EBIT is -4.72. The thresholds are as follows: Strongly Undervalued below -18.29, Undervalued between -18.29 and -11.50, Fairly Valued between 2.06 and -11.50, Overvalued between 2.06 and 8.84, and Strongly Overvalued above 8.84. The current Forward EV/EBIT of -0.58 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Portage Biotech Inc. (PRTG) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-0.34
P/OCF
Portage Biotech Inc. (PRTG) has a current P/OCF of -0.34. The 5-year average P/OCF is -4.08. The thresholds are as follows: Strongly Undervalued below -17.72, Undervalued between -17.72 and -10.90, Fairly Valued between 2.73 and -10.90, Overvalued between 2.73 and 9.55, and Strongly Overvalued above 9.55. The current Forward P/OCF of -0.34 falls within the Historic Trend Line -Fairly Valued range.
-0.42
P/FCF
Portage Biotech Inc. (PRTG) has a current P/FCF of -0.42. The 5-year average P/FCF is -5.10. The thresholds are as follows: Strongly Undervalued below -18.92, Undervalued between -18.92 and -12.01, Fairly Valued between 1.81 and -12.01, Overvalued between 1.81 and 8.72, and Strongly Overvalued above 8.72. The current Forward P/FCF of -0.42 falls within the Historic Trend Line -Fairly Valued range.
Portage Biotech Inc (PRTG) has a current Price-to-Book (P/B) ratio of -63.14. Compared to its 3-year average P/B ratio of 1.03 , the current P/B ratio is approximately -6231.43% higher. Relative to its 5-year average P/B ratio of 1.35, the current P/B ratio is about -4777.68% higher. Portage Biotech Inc (PRTG) has a Forward Free Cash Flow (FCF) yield of approximately -41.83%. Compared to its 3-year average FCF yield of -109.29%, the current FCF yield is approximately -61.72% lower. Relative to its 5-year average FCF yield of -66.67% , the current FCF yield is about -37.26% lower.
-63.14
P/B
Median3y
1.03
Median5y
1.35
-41.83
FCF Yield
Median3y
-109.29
Median5y
-66.67
Competitors Valuation Multiple
The average P/S ratio for PRTG's competitors is 0.00, providing a benchmark for relative valuation. Portage Biotech Inc Corp (PRTG) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PRTG increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PRTG in the past 1 year is driven by Unknown.
People Also Watch
FAQ

Is Portage Biotech Inc (PRTG) currently overvalued or undervalued?
Portage Biotech Inc (PRTG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.07. The fair price of Portage Biotech Inc (PRTG) is between to according to relative valuation methord.

What is Portage Biotech Inc (PRTG) fair value?

How does PRTG's valuation metrics compare to the industry average?

What is the current P/B ratio for Portage Biotech Inc (PRTG) as of Jul 30 2025?

What is the current FCF Yield for Portage Biotech Inc (PRTG) as of Jul 30 2025?

What is the current Forward P/E ratio for Portage Biotech Inc (PRTG) as of Jul 30 2025?
